40 results about "Immunodeficiency virus" patented technology

The present disclosure relates to pharmaceutical compositions comprising an HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

This disclosure relates to a method for preparing intermediates useful for preparing compounds that inhibit the function of human immunodeficiency virus (HIV) during the viral replication cycle, such as by disrupting the function of the HIV capsid shell. [Formula 1] JPEG2026524821000058.jpg39145

This invention provides a wide range of neutralizing antibodies targeting the epitopes of human immunodeficiency virus (HVM) or HIV. Furthermore, it provides compositions containing antibodies for use in prevention, and methods for the diagnosis and treatment of HIV infection. [Solution] An isolated anti-HIV antibody or its antigen-binding fragment is provided, comprising a heavy chain variable region containing a specific sequence and a light chain variable region containing a specific sequence. The antibody is a recombinant antibody or a human antibody.

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

The present invention relates to processes for preparing intermediates useful in the preparation of compounds that inhibit human immunodeficiency virus (HIV) function (e.g., disrupt HIV capsid function) during the viral replication cycle.

Peptides generating antibodies to human immunodeficiency virus (HIV) post-infection were identified. Higher antibody reactivity to these peptides was associated, with lower viral load post-infection.

The present disclosure relates to monoclonal human antibodies, or binding fragments thereof, directed against the CD4 binding site of human immunodeficiency virus HIV-1, pharmaceutical compositions comprising such monoclonal human antibodies, or binding fragments thereof, kits comprising such antibodies, or binding fragments thereof, and monoclonal antibodies or binding fragments thereof as well as pharmaceutical compositions and kits for use as medicaments and for the treatment or prevention of diseases caused by human immunodeficiency virus HIV-1.

The present disclosure relates to methods for determining the magnitude of a subject's immune response against a HIVACAT T-cell immunogen (HTI or “HTI immunogen”) and whether the subject can avoid antiretroviral therapy (ART). These methods are helpful for treating human immunodeficiency virus (HIV) and / or deciding whether to administer, continue or stop antiretroviral therapy in a subject. The present disclosure also relates to antigens, compositions, and kits related to such methods.

Provided herein are a vector for eradicating human immunodeficiency virus (HIV) from a human comprising a nucleic acid sequence encoding a dual-function protein that inhibits infectious HIV from budding from HIV-infected cells and represses replication of the vector in the absence of HIV. Methods of treating of HIV and kits are also provided.

Disclosed is a compound of formula (I): for treating or preventing a human immunodeficiency virus (HIV) infection in a mammal, for inhibiting or preventing maturation of an immature human immunodeficiency virus (HIV) to a mature HIV, and for preventing or inhibiting a human immunodeficiency virus (HIV) infection in a mammal having at least one HIV viral particle on a surface thereof.

The present invention relates to the field of virology. More specifically, the present invention provides compositions and methods useful for elimination of human immunodeficiency virus-1 (HIV-1) reservoir cells. In several embodiments, the single chain diabody binds human immunodeficiency virus 1 Envelope protein variable loops 1 and 2 (HIV-1 Env V1 / V2) and human type III Fcγ receptor (CD16). In a specific embodiment, the scDb comprises (a) an anti-HIV-1 Env V1 / V2 antigen binding fragment comprising a VH comprising or consisting of SEQ ID NO:1; (b) an anti-HIV Env V1 / V2 antigen binding fragment comprising a VL comprising or consisting of SEQ ID NO:5; (c) an anti-CD16 antigen binding fragment comprising a VH comprising or consisting of SEQ ID NO:17; and (d) an anti-CD16 antigen binding fragment comprising a VL comprising or consisting of SEQ ID NO:21.

Provided herein are methods, diagnostic instruments, and kits for detecting the presence or absence of an analyte associated with a disease in a subject. In some embodiments, the disease is Lyme disease, SARS-CoV-2, or a human immunodeficiency virus infection.

This disclosure is directed to pharmaceutical compositions and methods for treating or preventing HIV infection in a subject in need thereof. The composition can comprise an adenosine derivative that can be administered via injection, oral intake, implant, or a combination thereof.

The invention relates to the field of bioengineering, and discloses a human immunodeficiency virus p24 antigen and antibody detection kit and a preparation method thereof. The kit comprises a colloidal gold marker composite pad, wherein the colloidal gold marker composite pad comprises a p24 antibody colloidal gold marker, an HIV antigen colloidal gold marker and a chicken IgY antibody colloidal gold marker; an AG line, an AB line and a C line are arranged on the NC membrane, the AG line is coated with a p24 monoclonal antibody, the AB line is coated with HIV-I, HIV-II and HIV-O mixed antigens, and the C line is coated with goat anti-chicken IgY; and a sample pad, a conjugate pad and a water absorbent pad. The human immunodeficiency virus p24 antigen and antibody detection kit provided by the invention is obviously superior to the prior art in the aspects of sensitivity, specificity, convenience and stability, and has important clinical application and market values.

The present invention relates to monoclonal human antibodies or binding fragments thereof directed against the V3 glycan site of human immunodeficiency virus HIV-1, pharmaceutical compositions comprising such monoclonal human antibodies or binding fragments thereof, kits comprising such antibodies or binding fragments thereof, pharmaceutical compositions comprising such antibodies or binding fragments thereof, pharmaceutical compositions comprising such antibodies or binding fragments thereof, pharmaceutical compositions comprising such antibodies or binding fragments thereof, pharmaceutical compositions comprising such antibodies or binding fragments thereof, and pharmaceutical compositions comprising such antibodies or binding fragments thereof. And monoclonal antibodies or binding fragments thereof as well as pharmaceutical compositions and kits for use as medicaments and for the treatment or prevention of diseases caused by human immunodeficiency virus HIV-1.

Provided are a pharmaceutically acceptable salt, a crystal form and a preparation method of a TLR7 / 8 agonist compound of formula I, a pharmaceutical composition containing the pharmaceutically acceptable salt, and a medical use of the pharmaceutically acceptable salt, which can be used for preparing drugs for preventing or treating Toll-like receptor 7 / 8 (TLR7 / 8) related diseases, such as a new therapeutic agent for human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection and cancer.

The present disclosure relates to vaccine compositions against respiratory syncytial virus (RSV) that are tomato-based and their methods of production. The vaccine compositions comprise tomato fruit and plant-expressed fragment of RSV F protein, preferably the ectodomain of the RSV F protein. In some aspects, the vaccine compositions comprise tomato fruit and plant-expressed human immunodeficiency virus (HIV) virus-like particle (VLP) wherein the fragment of RSV F protein is displayed on the VLP surface. For example, the vaccine compositions are tomato paste spiked with the plant-expressed HIV VLP. In certain embodiments, the plant-expressed HIV VLP comprises a Gag protein; a fragment of gp41 protein, which comprises the C-terminal cytosolic domain of the gp41 protein; and a fragment of RSV F protein, wherein the fragment of RSV F protein lacks the p27 region and the C-terminus of the fragment of RSV F protein is linked to the N-terminus of the fragment of gp41 protein.

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

The invention provides a novel isoxazolopyrimidine derivative, a pharmaceutical composition and application of the novel isoxazolopyrimidine derivative, and belongs to the technical field of medicine synthesis. The novel isoxazolopyrimidine derivative provided by the invention can be used in drugs for inhibiting human immunodeficiency virus activity. The targeted drug inhibits interaction between the virus capsid protein and the host factor CPSF6, prevents nuclear input in HIV-1 virus infection and a transcriptional activation region positioning process, and achieves an efficient antiviral effect.

Provided herein are a vector for eradicating human immunodeficiency virus (HIV) from a human comprising a nucleic acid sequence encoding a dual-function protein that inhibits infectious HIV from budding from HIV-infected cells and represses replication of the vector in the absence of HIV. Methods of treating of HIV and kits are also provided.

Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I):including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R1, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

The present disclosure relates generally to combinations of compounds of Formula: (I) or Formula: (II) with a P-glycoprotein inhibitor. Also disclosed are pharmaceutical compositions comprising said combinations. The combinations of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present application provides a human immunodeficiency virus neutralizing antibody preparation and its use, specifically, the preparation comprises (a) a therapeutically effective amount of HIV neutralizing antibody; (b) a buffer with a concentration of 10-30 mmol / L; (c) a stabilizer; and (d) a surfactant, wherein the pH of the liquid preparation is 5.5-6.5. The preparation of the present application can not only effectively reduce the chemical degradation reaction rate of human immunodeficiency virus neutralizing antibody, improve the physical and chemical stability of the antibody, prolong the shelf life of the product, and reduce the number of drug bottles, but also can eliminate or reduce the side reactions of the injection site of the patient, and improve the drug comfort of the patient.

The present disclosure relates generally to solid forms of the compound of Formula I: Also disclosed are pharmaceutical compositions comprising said solid forms and methods of making said solid forms. The solid forms of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt theroof, and emtricitabine or a pharmaceutically acceptable salt thereof.

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I):including stereoisomers and pharmaceutically acceptable salts thereof. Methods associated with the preparation and use of the disclosed compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.

The present invention relates to human immunodeficiency virus (HIV) prevention and treatment. In particular, the present invention relates to a pharmaceutical composition comprising: Cabotegravir; a wetting agent; a stabilizer; and a tension regulator; wherein the Cabotegravir is present in the form of particles having a median mass diameter (X50) of between 2.5 m and 10 m (and including 2.5 m and 10 m).

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the prevention of a human immunodeficiency virus (HIV) infection in a patient.

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.